To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2

Condition:   COVID-19 Intervention:   Biological: Recombinant Novel Coronavirus vaccine (CHO Cells) Sponsor:   Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials